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Abstract
Background: The topology of a biological pathway provides clues as to how a pathway operates,
but rationally using this topology information with observed gene expression data remains a
challenge.
Results:  We introduce a new general-purpose analytic method called Mechanistic Bayesian
Networks (MBNs) that allows for the integration of gene expression data and known constraints
within a signal or regulatory pathway to predict new downstream pathway targets. The MBN
framework is implemented in an open-source Bayesian network learning package, the Python
Environment for Bayesian Learning (PEBL). We demonstrate how MBNs can be used by modeling
the early steps of the sonic hedgehog pathway using gene expression data from different
developmental stages and genetic backgrounds in mouse. Using the MBN approach we are able to
automatically identify many of the known downstream targets of the hedgehog pathway such as
Gas1 and Gli1, along with a short list of likely targets such as Mig12.
Conclusions: The MBN approach shown here can easily be extended to other pathways and data
types to yield a more mechanistic framework for learning genetic regulatory models.
Background
A general problem in systems biology is the integration of
observational experimental data such as gene expression,
with known pathways topologies. Ideally these two data
sources should be complementary, however in practice
there are few methods to systematically integrate these
two kinds of information. In this paper, we introduce a
method called Mechanistic Bayesian Networks (MBN) in
an attempt to use knowledge about the topology of a
pathway with gene expression data related to the same
pathway. As a sample case we used the topology of the
Sonic Hedgehog (Shh) signaling pathway as a model path-
way along with a targeted gene expression dataset. Using
these data we used the MBN approach to identify regula-
tory targets of the Shh pathway.
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Sonic Hedgehog (Shh) pathway
The Shh pathway plays a central role in organismal devel-
opment and the progression of some cancers [1]. Because
of its central role, the Shh pathway is well studied provid-
ing us with an ideal test case to validate our MBN
approach. The details of Shh are reviewed in detail else-
where [2-4], but here we will summarize the early steps of
the pathway that we will use in this work. Shh is a secreted
protein that acts as both a short-range contact-dependant
factor and as a long-range diffusible morphogen. The Shh
ligand binds its canonical receptor Patched1 (Ptch1),
which releases its inhibition of a second membrane-
bound protein, Smoothened (Smo). Derepression of Smo
in turn activates a signaling cascade inside the cell, even-
tually activating the Gli transcription factors and regulat-
ing the expression of a variety of genes. While some of the
downstream targets of the pathway are known, many
remain unknown. The initial steps of the pathway are
shown in Figure 1(c) with the terminal node GeneX rep-
resenting a putative downstream target. Note that in this
cascade, the Shh, Ptch1, and Smo proteins can all directly
or indirectly affect the target, although in different ways
and to different degrees. Figure 1(a) and 1(b) show more
abstracted representations of the pathway.
Due to its dose-dependant effect and role in development,
the Shh signal requires strict spatiotemporal control. The
pathway's known targets include pathway components,
promoters and antagonists, thus regulating the effects of
the Shh ligand over time. Cell surface proteins that pro-
mote Shh signaling, for example, are initially expressed in
Shh-responsive cells, sensitizing cells to even low levels of
the Shh ligand. As the level of Shh signaling increases,
downregulation of positive Shh components such as Gas1
and upregulation of negative components such as Ptch1,
Ptch2, and Hhip that sequester the ligand ensure a tight
BN and MBN modeling of Shh pathway Figure 1
BN and MBN modeling of Shh pathway: (a) A sequential BN model of the pathway that omits protein activity, (b) a paral-
lel BN model of the pathway, and (c) an MBN model of the pathway. The ovals Shh, Ptch1 and Smo represent mRNA measure-
ments, while the ovals, ShhP, Ptch1P and SmoP, represent proteins. The oval GeneX indicates a candidate downstream 
expression target of the pathway. Dotted ovals represent entities that are known in the mechanism but are not observed, 
while unbroken ovals represent experimentally observed variables. Arrows between nodes represent a directional interaction 
but do not specify the functional form.
Observed variable
Unobserved variable
Directional interaction
Template node
Shh Ptch1 Smo GeneX a)
Shh Ptch1 Smo
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control over Shh signaling [5]. Additionally, Shh is known
to cooperate with or antagonize other pathways such as
Bmp [6], retinoic acid [7,8], Wnt [9], Ras [10], and Notch
[11] in a time-, dose-, and spatially-dependant manner.
These factors further complicate the identification of path-
way targets.
The Shh pathway raises a more general problem: given
gene expression data from multiple samples, tissue and
organs under different genetic knockout conditions, how
can we identify downstream targets of a given pathway?
Due to the interactions between different pathways and
multiple cascades between ligand reception and eventual
transcriptional regulation, it is not clear what constitutes
a downstream target of a specific pathway. Common anal-
ysis approaches include significance testing between sam-
ples, differential expression, and clustering [12]. While
these approaches are widely used and helpful, they fail to
incorporate knowledge of the underlying pathway. When
the pathway information is used, it is done while ignoring
fundamental biological knowledge such as the central
dogma. DNA, mRNA, and proteins are conflated into one
variable and specific interactions such as protein-protein
or protein-DNA are implicitly assumed to be detectable
via gene expression data. To circumvent this problem, we
present a novel mechanistic Bayesian network approach
that more closely respects the meaning of both the path-
way and the expression data.
Methods
In the following sections we describe the theoretical
underpinnings of the MBN framework and provide a
method for evaluating the significance of a result. Next we
describe how we tested the MBN method using gene
expression data from gene knockout mouse models to
identify targets of the Shh pathway.
Mechanistic Bayesian Networks: Theory and Definition
Mechanistic Bayesian networks represent a subset of a
general class of analysis tools called Bayesian Networks
(BN). A BN is a probabilistic graphical model that
encodes dependencies between variables in a compact
and descriptive manner. A BN can be represented as a
graph with nodes representing variables and edges repre-
senting dependencies or relationships between the varia-
bles. Mathematically, each node describes a conditional
probability distribution (CPD) that quantitatively models
the relationships between a node and its parent nodes.
Note that an edge (an arrow) between two variables indi-
cates a directed relationship but does not specify the func-
tional form of the relationship. Said another way, an edge
in a Bayesian network does not indicate activation, inhibi-
tion or any other specific function. This interpretation of
an edge differs from the usual definition of an edge in a
signaling pathway, where edges are often assumed to have
a defined effect. The advantage of the more broad edge
definition is that the relationships between nodes in a
Bayesian network can be more complex and include func-
tions that are nonlinear, multimodal, or logical.
BNs have been used successfully to model complex phe-
nomenon in many fields and in systems biology, in par-
ticular, to model gene-regulatory networks, protein-
interaction networks, signaling networks and to integrate
heterogeneous biological data [13-17]. Methods for train-
ing and learning BNs are well established [18,19] and are
available in a large number of software applications [20].
In contrast to the more general Bayesian network, a Mech-
anistic Bayesian Network (MBN) adheres more closely to
known biological mechanisms by differentiating between
mRNA transcripts and proteins, and by including path-
way-based structural constraints. Because most studies do
not measure both protein and gene expression, unknown
quantities in an MBN are treated as unobserved, latent
variables. By creating models that more closely resemble
the known mechanism, MBNs effectively incorporate in
additional information that is not available in the experi-
mental data alone.
Mechanistic Bayesian Network Templates
When analyzing a biological system, users often want to
generate and rank a set of entities that match certain con-
straints, such as "all downstream targets of the Shh path-
way" or "all proteins that participate in the crosstalk
between the Shh and Wnt pathways". While it is possible
to devise specific sets of constraints and methods for each
case, we propose a generic MBN based template approach.
Each set of constraints is expressed as an MBN template
from which specific MBNs are instantiated and evaluated
against an experimental dataset. An MBN template is
composed of two types of nodes: constant and template
nodes. A constant node is a regular node corresponding to
either one variable in the dataset or an unobserved varia-
ble while a template node is a holding place for variables
in the dataset. Each instantiation of the template is a reg-
ular MBN that can be scored using existing BN methods.
Maximum Entropy Discretization of the data
Before MBN can be applied to a dataset, the data must be
discretized into a finite set of bins. While there are many
ways to bin data, we use the Maximum Entropy principle
to derive our discretization scheme. The principle states
that the distribution that maximizes the information
entropy is the true distribution given testable information
[21].
Accordingly, we bin our data such that each bin contains
the same number of data points as this maximizes the
entropy of the distribution. There is no theory prescribingBMC Bioinformatics 2009, 10:433 http://www.biomedcentral.com/1471-2105/10/433
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the optimal number of bins for any given dataset or ana-
lytical method; increasing the number of bin decreases the
information loss incurred during discretization but also
increases the number of parameters and thus decreases
the statistical power of the analysis given the same data
samples. Most modelers working with systems biology
data have arrived at three bins as a suitable compromise
between information loss and statistical power
[13,15,22].
Calculating the Posterior Probability of a Model
Once the data are discretized, a particular model topology
can be scored as the posterior probability of a model given
data, given below.
P(M|D) is the posterior probability of the BN or MBN
model M given the data D. Said another way, P(M|D) is
our belief that the model M is correct after having
observed the data D. P(M) is the prior probability of the
model, that is, our belief that the model M is correct
before having observed the data D. The prior probability
allows us to integrate model probabilities computed using
other methods and data. P(D|M) is the likelihood that the
data was generated from the model M while P(D) is a scal-
ing factor that is usually ignored. P(D|M) is calculated as
the likelihood after marginalizing over all model parame-
ters given a network structure.
In the MBN framework, a Bayesian network is modeled
using a multinomial representation with Dirichlet priors
for the relationships between variables. This representa-
tion is convenient in that it is relatively agnostic to func-
tional forms and has a convenient closed form solution,
the Bayesian Dirichlet Equivalent (BDe) metric, described
below.
BDe Scoring Metric: An approximation for the Marginal 
Likelihood
The MBN approach uses the BDe scoring metric [19] to
calculate the marginal likelihood of a dataset given a
model. The BDe metric is a closed form solution to the
marginal likelihood for a multinomial Bayesian network
model with Dirichlet priors. The BDe metric is expressed
as:
where Γ(l) is the Gamma function, n is the number of
nodes, ri is the arity of node i, qi is the arity of πi (the parent
set of node i), Nij is the number of samples where πi is in
configuration j, Nijk is the number of sampler where πi is
in configuration j and the node has value k and αij and αijk
are the prior counts corresponding to Nij and Nijk respec-
tively. A full derivation of the BDe metric is described else-
where [19].
In practice, the BDe metric is represented in log-space for
computational convenience. Because of this log transfor-
mation, all BDe scores in this paper will be negative.
Calculating the Marginal Likelihood with Missing Data
If we have some missing values or latent variables in the
dataset, we can use an altered method for computing the
marginal likelihood. Because the likelihood is no longer
fully factorizable into the product of the probabilities for
each variable, we must calculate the marginal likelihood
given every potential completion of the missing data. The
simplest method is to marginalize over all possible sets of
values for the missing data and take the average. However,
this exact enumeration approach is impractical for non-
trivial cases and so a heuristic must be used.
In this work we will used a modified Gibbs sampling [19]
approach to approximate the marginal likelihood. We
alter the method to only sample missing data completions
that result in a maximum entropy discretization for all
variables. This maximum entropy requirement ensures
that p(xi) = p(xj) for all sets of variables and eliminates
bias due to differential discretization for observed and
hidden variables.
Calculating the Marginal Likelihood with Interventions
When calculating the marginal likelihood, data from
interventions such as genetic knockouts are handled dif-
ferently. If a particular data sample is the result of an inter-
vention on a set of variables, the values for those variables
no longer depend on their parent sets. They are, instead,
arbitrarily set as the result of the intervention. Accord-
ingly, the specific variable samples are ignored when con-
structing the multinomial table for any node that was
intervened upon [23].
Assessing Model Significance with Bootstrapping based p-
values
To evaluate the significance of an MBN prediction, we cal-
culate a p-value for each MBN result using nonparametric
bootstrapping [24]. In this approach, we generate a large
number of MBN models with template nodes replaced by
randomly generated variables with the same discretiza-
tion schemes as the observed variables. The scores for
these MBN models are used as the null model against
which MBN scores are compared to determine p-values.
Due to the computational time required to score each
bootstrap sample, we can only resolve p-values down to
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.001 and cannot correct for multiple hypothesis testing.
We acknowledge that correction for multiple testing
would lower the significance of each result.
Using MBN Templates to Define and Identify Downstream 
Targets of the Shh Pathway
To determine the downstream targets of the Shh pathway,
we created an MBN template based on the canonical path-
way as described in literature with a terminal downstream
template node as shown in Figure 1(c). Specific MBN
models are instantiated from the template by replacing
the template node (the candidate target gene) with a spe-
cific gene from the dataset. Thus, each instantiated MBN
model is a separate hypothesis that can be evaluated
against the experimental data.
Experimental Data
To test our approach, we assembled data from three
mouse models with gene knockouts in Shh, Ptch1, and
Smo described in more detail elsewhere [25]. Briefly, sam-
ples from different embryonic tissues at varying develop-
mental stages were assayed using the U74v2 Affymetrix
microarrays to determine the expression profile. Not all
combinations of developmental stages and genetic back-
grounds were available due to prenatal lethality for Ptch1
and  Smo. Samples assayed include 6-8-somite-stage
(approximately 8.5 days post fertilization) with wildtype,
Smo-/-, and Ptch1-/-  backgrounds; 10-13 somite-stage
(approximately 8.75 days post fertilization) with
wildtype, Smo-/-, and Ptch1-/- backgrounds; 10.5 days post
fertilization embryo samples from head, trunk, and limb
bud with wildtype and Shh-/- backgrounds. The experi-
mental design is summarized in Table 1.
Data Preprocessing
The raw gene expression data (.CEL files) were processed
using RMA [26] as implemented in the Bioconductor Affy
package [27]. The data were annotated using updated
probeset definitions (.CDF files) provided by the Microar-
ray Lab at the University of Michigan [28].
Data were discretized into 3 bins using the Maximum
Entropy discretization scheme described above. Because
the data contain samples from varying developmental
stages and genes with significant expression variation
between stages, genes were discretized separately for each
tissue type. This discretization scheme allowed the soft-
ware to more easily identify relevant patterns within a tis-
sue type. Genes were knocked out by altering the sequence
to create inactive protein. Thus, for a knockout on a par-
ticular gene, the gene's expression was left unaltered but
the protein expression was set to 0 and the value was
marked as an intervention so it could be handled differ-
ently by the scoring procedure.
MBN Template Analysis
To test the MBN template system using the Shh dataset,
we developed a template that matched the topology
shown in Figure 1(c). In this template, we search for a
downstream target node, GeneX, that responds to the Shh
signaling cascade. In this search, we assume that each gene
has an equal prior probability of being the target node,
and all relationships are scored using the BDe score and a
Gibbs sampler, described above.
Using this template, we generated 6299 candidate MBN
models -- one for each candidate target gene that showed
significant differential expression. Due to the custom CDF
annotation, Smo was not present on the chip, thus we
modeled the Smo mRNA expression as a hidden node. No
protein expression was observed in this experiment, so
nodes representing protein concentrations or activities
were also modeled as hidden. Rather than selecting the
number of iterations for the Gibbs sampler a priori, we
calculated the posterior distribution P(M|D) with 150 K
iterations, then with 300 K iterations. Although the sam-
pler had largely converged at this point as evidenced by
the observation that the top 25 results did not change sig-
nificantly, we resumed the Gibbs's sampler for the 300 k
run and sampled another 300 K iterations for a total of
600 K iterations per MBN model. The computation took
approximately 5.6 minutes per MBN for a total of approx-
imately 12 hours on a 48-node compute grid. P-values
were calculated with bootstrapping describe above using
1054 MBN models to represent the null distribution. All
code and data required to replicate the analysis are
included in Additional file 1 [see Additional file 1]. The
code can be easily modified to run similar analysis on dif-
ferent dataset using different MBN templates.
Table 1: Experimental design for gene expression data
Developmental stage and location wt Shh-/- Ptch1-/- Smo-/-
Embryonic day 8.5
whole embryo
33 3
Embryonic day 8.75
whole embryo
33 3
Embryonic day 10.5
head
44
Embryonic day 10.5
limb bud
66
Embryonic day 10.5
trunk
33
Experimental design for gathering gene expression data from a range 
of developmental stages, locations, and genetic backgrounds. Columns 
indicate the genetic background of the mouse model, rows indicate 
the developmental stage and location of the samples and the numbers 
within the table cell indicate the number of samples assayed.BMC Bioinformatics 2009, 10:433 http://www.biomedcentral.com/1471-2105/10/433
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In addition, we also tested two alternative Bayesian
approaches shown in Figure 1(a) and 1(b). These
approaches use topologies that are simpler than the MBN
approach in 1(c), but less closely adhere to the known
mechanism of the biochemistry of the pathway.
Results and Discussion
In the following sections we show the results from the
MBN analysis of the Shh knockout dataset and discuss the
biological plausibility for each finding. Next we discuss
expected hedgehog pathway target genes that were not
identified by the MBN and a comparison with other tech-
niques.
The predicted target genes from the MBN analysis are
shown in Table 2. The top scoring hits include many
known Shh targets as described below. The top hit, Gas1,
has been shown to be a negative target of Shh signaling
whereas knockout and subsequent gain-of-function stud-
ies have shown Gas1 to be a positive component of the
Shh pathway that acts synergistically with Ptch1 to bind
the hedgehog ligand [5]. The second target, Gli1, is one of
the three Gli transcription factors that regulate Shh target
genes and is often used as a canonical readout of Shh
activity. Shh signaling is known to both induce Gli1
expression and also regulate its nuclear accumulation and
therefore its activity [29]. Ptch2 is a homolog of Ptch1 but
has a slightly different expression pattern. Like Ptch1,
Ptch2 is known to be transcriptionally modulated by Shh
signaling [30]. Knockout studies have shown that Shh sig-
naling is required for expression of Msx1, a transcriptional
repressor with a putative role in limb-pattern formation
[31]. Foxc2 and Foxd1 have been shown to be upregulated
by Shh signaling in null, conditional, and constitutively
active Smo mutant backgrounds [32].
Beyond these known Shh-related genes, some of the
highly ranked results appear to be novel putative Shh tar-
gets. Mig12 binds the Opitz syndrome gene Mid1 and the
complex is thought to stabilize microtubules [33]. Mid1 is
repressed by Shh [34] and this is partially borne out by our
gene expression results which show a positive influence
from Shh and a negative influence from Ptch1. Interest-
ingly though, our analysis shows Mid1 to be a poor target.
Mig12 is not a known Shh target but is a significant result
in our analysis and appears to be upregulated by the Shh
pathway.
Both cellular retinoic acid binding proteins, Crabp1 and
Crabp2, score well in our analysis but are not known Shh
targets. In some developmental processes, retinoic acid
(RA) has been shown to work synergistically with Shh to
create the zone of polarizing activity, [7] for example, and
in adult pluripotent stem cells [8]. Crabp binds RA with
high affinity and is thought to spatially modulate the
effect of RA by adjusting the concentration of RA reaching
the nucleus [35]. One interpretation of the MBN result is
Table 2: Top 10 results from the MBN analysis (model in Figure 1c).
Gene Bayesian Score P-value Shh Correlation Ptch1 Correlation Citations
Gas1 (Growth arrest specific 1) -226.34 < .001 -0.016 -0.57 [5]
Gli1 (GLI-Kruppel family member) -226.69 < .001 0.61 0.74 [29]
Ptch2 (Patched homolog 2) -229.17 < .001 0.54 0.69 [30]
Gtpbp4 (GTP binding protein 4) -229.44 < .001 -0.28 0.35
Mig12 (Mid1 interacting protein 1) -229.61 < .001 0.20 0.61
Msx1 (Homeo box, msh-like 1) -229.87 < .001 0.03 -0.56 [31]
Crabp2 (Cellular retinoic acid binding protein II) -229.97 < .001 -0.05 -0.46
Has2 (Hyaluronan synthase 2) -231.03 < .001 -0.08 0.46
Foxd1 (Forkhead box D1) -231.61 < .001 0.29 0.43 [32]
Ak1 (Adenylate kinase 1) -232.22 < .001 0.16 -0.01
The columns specify the gene name and a short description; the Bayesian score as described in Methods; the resulting p-value for the Bayesian 
score calculated using a bootstrap method as described in Methods; a linear correlation to the Shh transcript; a linear correlation to the Ptch1 
transcript; and a literature citation, if available, that specifies that the gene is indeed a true downstream target of the Shh pathway.BMC Bioinformatics 2009, 10:433 http://www.biomedcentral.com/1471-2105/10/433
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that that Shh modulates the effects of RA by regulating
Crabp.
Known Shh targets not identified by the MBN
Our results, however, do fail to identify some known and
expected targets. For example, one might expect the genes
Foxa2, Gli2, Gli3, and Ihh to be identified by the MBN as
these are often listed as targets of the Shh pathway, but in
our analysis they did not score near the top. The MBN
template used in this analysis (Figure 1) detects relation-
ships between a candidate target and Shh and Ptch1, con-
strained by the information bottleneck introduced by the
hidden protein nodes. When we examine the relationship
between the expected but poorly scoring genes and Shh
and Ptch1 (Figure 2), we find no consistent pattern of dif-
ferential expression. It is clear that the expression does not
change significantly or consistently with the pattern of
change for Shh or Ptch1. Genes identified as targets by the
MBN such as Gas1, Gli1, Ptch2, Crabp1 and Foxd1, show
clear relationships that can be assessed by eye.
Comparison of MBN Analysis and non-Bayesian 
Bioinformatics Techniques
The results we obtain using MBN are different than those
from standard techniques for determining downstream
pathway targets. Whereas clustering, differential expres-
sion and significance testing are, in general, unable to
identify nonlinear and multimodal relationships, Baye-
sian methods such as MBN do not have this limitation.
Bayesian methods learn based on complex patterns of
change rather than the magnitude of change or a simple
linear correlation.
When we use differential expression as an indicator of sig-
nificance, for example, we find none of the canonical tar-
gets near the top of the list [see Additional file 2]. Gli1, the
commonly used indicator of Shh activity, ranks 629th in
terms of fold-change, but 2nd with respect to MBN analy-
sis. This difference is expected, however, because only
small changes in gene expression are required to modu-
late the activities of transcription factors and pathway
components that participate in feedback loops with the
Shh ligand. We obtain slightly better but still poor results
when identifying targets based on a linear correlation to
either Shh or Ptch1 gene expression. This difficulty with
clustering can be seen in Table 2. Clustering methods suf-
fer from similar failures as linear correlation and fail to
take into account known information about the initial
steps of the pathway.
Comparison of MBN and BN modeling of the Shh Pathway
To isolate the effect of the MBN template over more stand-
ard BN approaches, we ran a direct comparison between
the approaches using the three topologies shown in Figure
1. The simplest translation of the Shh pathway, shown in
Comparing the relative gene expression profile of 8 selected  putative targets Figure 2
Comparing the relative gene expression profile of 8 
selected putative targets. From these expression pat-
terns one can see that the profiles for Gas1 and Gli1 closely 
follow changes in Shh and Ptch1 expression. Gli2 and Gli3 
show higher activation in the adult tissues as compared to 
the somite samples but, even in the adult tissues, their 
expression pattern does not correspond to the knockout 
state of Shh. Foxa2 expression shows a strong response to 
the Ptch1 knockouts in the somite samples and with Shh 
knockouts in the adult head tissues but there is no pattern in 
the adult limb and trunk tissues. While the patterns in Gli2, 
Gli3, Foxa2 are significant, the patterns either do not coincide 
with patterns in the early steps of the Shh pathway (Shh, 
Ptch1, Smo) indicating that there may be other genes involved 
in their regulatory control or the patterns do not hold over 
all tissues. Accordingly, those genes do not score highly in 
the MBN method.
     Samples
Sample groups:
 1. X8 somite, Ptch1-/- (3)
 2. X8 somite, Smo-/- (3)
 3. X8 somite, wt (3)
 4. X13 somite, Ptch1-/- (3)
 5. X13 somite, Smo-/- (3)
 6. X13 somite, wt (3)
  7. Head, Shh-/- (4)
  8. Head, wt (4)
  9. Limb bud, Shh-/- (6)
10. Limb bud, wt (6)
11. Trunk, Shh-/- (3)
12. Trunk, wt (3)
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Figure 1(a), is to interpret the qualitative diagram as a BN
and replace all arrows with a Bayesian edge to produce a
sequential model. Although the topology looks most sim-
ilar to a biochemical diagram, for a Bayesian network the
topology indicates that only Smo influences the target
gene. An alternative topology is shown in Figure 1(b). In
this parallel topology, the target gene is influenced by all
of the genes in the pathway. However, this topology does
not capture the unobserved proteomic effects, nor does
the topology distinguish between the relative position of
Shh, Ptch, and Smo in the signaling pathway
The results for the three topologies depicted in Figures
1(a), 1(b) and 1(c) are shown in Tables 3, 4 and 2 respec-
tively. When we compare the results, we find that the tar-
get genes predicted by the MBN topology (Figure 1(c))
best match what is known about the pathway. If we com-
pare the number of known targets identified in the top 10
targets predicted by each method we find the MBN pre-
dicts 5/10, the parallel topology predicts 4/10, and the
sequential topology predicts 2/10. In the MBN results,
Gas1, Gli1 and Ptch2 rank 1st, 2nd, and 3rd respectively and
are all well-known Shh targets, while in the sequential
Table 3: Top 10 results from the sequential BN analysis (model in Figure 1a).
Gene Bayesian Score Citations
Ak1 (Adenylate kinase 1) -80.30
Ubc (Ubiquitin C) -81.84
Pdcd4 (Programmed cell death 4) -81.90
Nckap1 (NCK-associated protein 1) -81.90
Crabp2 (Cellular retinoic acid binding protein II) -82.07
Ntn1 (Netrin 1) -82.60 [37]
Oprs1 (Opioid receptor, sigma 1) -82.70
Fgf8 (Fibroblast growth factor 8) -82.84 [6]
Nme6 (Expressed in non-metastatic cells 6, protein) -83.10
Gtf3c5 (General transcription factor IIIC, polypeptide 5) -83.10
The columns specify the gene name and short description; the Bayesian score as described in Methods; and a literature citation, if available, that 
specifies that the gene in indeed a true downstream target of the Shh pathway.
Table 4: Top 10 results from the parallel BN analysis (model in Figure 1b).
Gene Bayesian Score Citations
Foxc2 (Forkhead box C2) -115.16 [32]
Gli1 (GLI-Kruppel family member GLI1) -116.19 [29]
Ntn1 (Netrin 1) -117.24 [37]
Ptch2 (Patched homolog 2) -117.24 [30]
Gspt1 (G1 to S phase transition 1) -117.39
Mid1ip1 (Mid1 interacting protein 1) -117.39
B4galt3 (UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 3) -117.51
Cklfsf8 (Chemokine-like factor super family 8) -118.05
Ptprz1 (Protein tyrosine phosphatase, receptor type Z, polypeptide 1) -118.20
Dctn3 (Dynactin 3) -118.42
The columns are identical to those in table 3.BMC Bioinformatics 2009, 10:433 http://www.biomedcentral.com/1471-2105/10/433
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model these genes rank 11th, 2nd and 3rd respectively, and
in the parallel model these genes rank 24th, 20th and 21st
respectively. One reason for this discrepancy is that the BN
models impose fewer constraints on the candidate gene
which would produce more false positives -- a result in
line with what we see. The full lists of target genes for each
topology is provided in Additional file 2.
Extension to larger MBN templates
While we used a small template pathway in this work as a
proof of concept, the method can be applied to larger
pathways in a similar way. However, large numbers of
hidden nodes increase the computational requirements
and may make the analysis intractable using the Gibbs
sampler used in this work. The MBN template algorithm's
runtime complexity is O(nm2h2) where n is the number
of candidate genes, m in the number of data samples and
h is the number of hidden or latent variables. Because the
limiting step is the Gibbs sampling's O(m2h2) runtime
complexity, we could use a more complex but efficient
heuristic sampling method such as variational learning
[36]. As currently implemented, MBN templates should
be limited to models with a small number of hidden
nodes.
Extension of MBNs to other data types
Although this study focused on gene expression data, the
MBN template method can be used with any type of
observed data that can be represented in the pathway. If a
molecular entity can be represented in an MBN template
while being faithful to the underlying biochemical mech-
anisms, data regarding the molecule's concentration or
activity can be used. Possible other measurements that
could be used with a similar MBN approach include pro-
tein expression, kinase activity, and miRNA expression.
Furthermore, MBN templates can be used to integrate
observations for multiple data types assuming that the
measurements are made on a common set of samples.
Conclusion
We have shown how MBNs can be used to integrate gene
expression data and known topological information to
uncover mechanistic details about complex pathways.
Although we have shown only one example with finding
downstream targets of the Shh pathway, a similar
approach could be used on other pathway topologies,
data types, and to identify targets at different locations in
the pathway. In this example, the MBN method provided
better target predictions than other methods, due in part
because the topology assumed by the MBN is closer to the
known biochemical mechanism.
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MBN: mechanistic Bayesian network; BN: Bayesian net-
work
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